In fact, AR has been present in the majority of primary and metastatic PCa and approximately 80 to 90% of the PCa cases depend on androgen at an early stage, hence the first approach tends to be androgen therapy ablation with the goal to decrease androgen levels and suppress AR [14]. The gene discussed is AR; the disease is posterior cortical atrophy.